ECRG2 Antibody Cat. No.: 6523

Availability: In stock

$0.00

 Price Options

$0.00
psi-iconSpecifications
HOST SPECIES:Chicken
SPECIES REACTIVITY: Human, Mouse, Rat
IMMUNOGEN: ECRG2 antibody was raised against a 16 amino acid synthetic peptide near the carboxy terminus of human ECRG2.

The immunogen is located within the last 50 amino acids of ECRG2.
TESTED APPLICATIONS: ELISA, IHC-P, WB
APPLICATIONS: ECRG2 antibody can be used for detection of ECRG2 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL.

Antibody validated: Western Blot in mouse samples and Immunohistochemistry in rat samples. All other applications and species not yet tested.
SPECIFICITY: ECRG2 antibody is predicted to not cross-react with other ECRG family members
POSITIVE CONTROL:1) Cat. No. 1288 - A20 Cell Lysate
PREDICTED MOLECULAR WEIGHT: Predicted: 9 kDa

Observed: 14 kDa

psi-iconProperties
PURIFICATION:ECRG2 Antibody is affinity chromatography purified via peptide column.
CLONALITY:Polyclonal
ISOTYPE:IgY
CONJUGATE:Unconjugated
PHYSICAL STATE:Liquid
BUFFER:ECRG2 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:ECRG2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

psi-iconAdditional Info
OFFICIAL SYMBOL:SPINK7
ALTERNATE NAMES:ECRG2 Antibody: ECG2, ECRG2, ECG2, UNQ745/PRO1474, Serine protease inhibitor Kazal-type 7, Esophagus cancer-related gene 2 protein, ECRG-2
ACCESSION NO.:AAI09386
PROTEIN GI NO.:14211875
GENE ID:84651
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
psi-iconBackground and References
BACKGROUND:ECRG2 Antibody: The esophageal cancer-susceptibility gene 2 (ECRG2), also known as SPINK7, is a novel tumor suppressor gene identified from the human esophagus. It interacts directly with metallothionein 2A and urokinase-type plasminogen activator (uPA), and downregulates the activity of uPA, leading to reduced cancer cell migration, invasion and metastasis. ECRG2 forms a complex with uPA and its receptor uPAR, modifying the dynamic association of uPAR with beta1 integrins and disrupting the Src/MAP kinase pathway that normally stimulates cell migration and invasion. ECRG2 may thus represent a novel therapeutic target for cancer.
REFERENCES:1) Cui Y, Wang J, Zhang X, et al. ECRG2, a novel candidate of tumor suppressor gene in the esophageal carcinoma, interacts directly with metallothionein 2A and links to apoptosis. Biochem. Biophys. Res. Commun. 2003; 302:904-15.
2) Huang G, Hu Z, Li M, et al. ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity. Carcinogenesis 2007; 28:2274-81
3) Cheng X, Shen Z, Yin L, et al. ECRG2 regulates cell migration/invasion through the urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway. J. Biol. Chem. 2009; 284:30897-906

ANTIBODIES FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.